FindTrial
Sign In

Understanding the role of pyrimidine compound in breast cancer

Evaluation of the action mechanism of pyrimidine compound in the regulation of hormonal receptors in breast cancer - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/11/059474
Enrollment
5
Registered
2023-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

PRAMOD KUMAR AVTI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In this study only female breast cancer patients will be included. Breast cancer patients age18- 60 years. The diagnosis of the patient through mammographic techniques. Patients at all stages of the disease will be included. Surgery or mastectomy patients will be included. With or without treatment patients will be included in this study.

Exclusion criteria

Exclusion criteria: Age 60. Patients with a psychiatric disorder. Patients with multiple malignancies.

Design outcomes

Primary

MeasureTime frame
1. Post surgical breast tumor tissue/blood will be collected for hormonal receptor expression. Timepoint: 2. The collected tissue samples analysis will be performed within 4-6 weeks—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDR DIVYA DAHIYA

POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH

pramod.avti@gmail.com9876955337

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026